Cantor Fitzgerald Reiterates Overweight on Insmed, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on Insmed (NASDAQ:INSM) and maintained a price target of $46.
September 19, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Insmed's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $46.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Insmed. The maintained price target of $46 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100